ARS Pharmaceuticals Nears Profitability Timeline While Prescription Growth Masks Cost Questions

ARS Pharmaceuticals (NASDAQ: SPRY) reports Q2 2026 earnings after market close on August 13, 2026, with analysts expecting a loss of $-0.55 per share on revenue of approximately $31.69 million. The central question for investors is whether the company can demonstrate improving profitability trends and sustained prescription growth for its flagship Neffy product, or if mounting losses and elevated operating expenses will continue to pressure the stock. With shares down 68% year-to-date and trading near 52-week lows, this report could prove pivotal in determining whether the recent selloff represents capitulation or further downside ahead.

Part 1: Earnings Preview

ARS Pharmaceuticals is a commercial-stage biopharmaceutical company focused on emergency treatments for severe allergic reactions, with its lead product Neffy—the first needle-free epinephrine nasal spray approved for anaphylaxis. The company represents a novel approach in the emergency allergy treatment market, competing against traditional EpiPen injectors with a more patient-friendly delivery mechanism.

For Q2 2026, analysts expect ARS Pharmaceuticals to report a loss of $-0.55 per share on revenue of approximately $31.69 million, with estimates ranging from $-0.61 to $-0.49 per share. The company most recently reported Q1 2026 earnings of $-0.61 per share, missing estimates of $-0.53 by 15.09%. Year-over-year, the consensus estimate represents a 19.57% deterioration from the $-0.46 loss reported in Q2 2025, reflecting the company's continued investment phase despite revenue growth.

Three key themes define this earnings story:

Neffy Prescription Momentum vs. Profitability Path: Neffy prescriptions tripled year-over-year in Q1, demonstrating strong commercial traction for the needle-free delivery system. However, investors are watching whether this growth can accelerate further while the company navigates a path toward profitability. With selling, general, and administrative expenses reaching $72.2 million in Q1—exceeding quarterly revenue by more than 3x—the sustainability of the current burn rate remains a critical concern.

Revenue Growth Trajectory: Revenue of $22.68 million in Q1 slightly exceeded estimates, and the $31.69 million consensus for Q2 would represent 40% sequential growth. Investors will scrutinize whether this acceleration is sustainable and driven by organic prescription growth or influenced by channel inventory dynamics and one-time factors.

Cash Runway and Operating Leverage: With $201 million in cash and short-term investments as of Q1, ARS Pharmaceuticals maintains a solid balance sheet. However, the company's ability to demonstrate improving operating leverage—growing revenue faster than expenses—will be crucial in determining whether it can reach cash flow breakeven without requiring additional capital raises that could dilute shareholders.

Analyst commentary ahead of the release reflects cautious optimism tempered by profitability concerns. While the Street maintains a bullish stance on Neffy's commercial potential and differentiated product profile, the consistent pattern of earnings misses and widening losses has weighed on sentiment. The stock's 8.56% pre-market plunge following Q1 results and subsequent 31% year-to-date decline underscore investor impatience with the pace of improvement.

Part 2: Historical Earnings Performance

ARS Pharmaceuticals has established a concerning pattern of earnings disappointments over the past four quarters, consistently missing analyst estimates. The company reported losses of $-0.46 (vs. $-0.41 estimate), $-0.52 (vs. $-0.45 estimate), $-0.42 (meeting the $-0.42 estimate), and most recently $-0.61 (vs. $-0.53 estimate), representing surprise rates of -12.20%, -15.56%, unchanged, and -15.09% respectively.

The trend shows deteriorating performance, with three of the past four quarters delivering double-digit percentage misses. The Q1 2026 miss of 15.09% was particularly notable, as the $-0.61 loss represented a significant step backward from the $-0.42 result in Q4 2025. This pattern suggests the company is struggling to control costs and achieve operating leverage as it scales Neffy's commercial launch.

The consistency of these misses—with only one quarter meeting estimates over the past year—indicates systematic challenges in forecasting profitability or managing expenses relative to revenue growth. This track record has likely contributed to the stock's sharp decline and will make investors particularly skeptical heading into Q2 results, placing additional pressure on management to deliver a cleaner quarter or provide credible guidance for improvement.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

ARS Pharmaceuticals typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 8.49% and Day +1 move of 4.03%. The stock has demonstrated particularly dramatic swings, including a 22.83% surge on Day 0 in March 2025 followed by a 13.63% reversal the next day, and a 15.23% decline in November 2024. Most recently, the May 2026 earnings triggered a 6.49% Day 0 decline followed by a more modest 1.68% Day +1 drop.

The average Day 0 trading range of 14.82% indicates substantial intraday volatility as investors position ahead of results, while the Day +1 range of 8.77% shows continued uncertainty in the immediate aftermath. The pattern suggests SPRY tends to see its largest moves on the day following earnings (Day +1 for after-hours reporters), with follow-through action often extending the initial reaction rather than reversing it. Investors should prepare for potential double-digit percentage swings in either direction based on whether the company can break its recent pattern of disappointing results.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 16.86% through the August 21 expiration, significantly higher than the stock's average historical Day 0 move of 8.49% and even exceeding the average Day 0 range of 14.82%. This elevated implied volatility of 116.19% suggests options traders are anticipating a more dramatic reaction than typical, possibly reflecting heightened uncertainty around the company's ability to demonstrate improving fundamentals after several quarters of disappointments.

Part 3: What Analysts Are Saying

Analysts maintain a bullish consensus on ARS Pharmaceuticals despite recent stock weakness, with an average rating of 4.60 out of 5.0 (Strong Buy territory). The current breakdown shows 4 Strong Buy ratings and 1 Hold, with no sell recommendations. The average price target of $28.67 implies substantial 374% upside from the current price of $6.05, with individual targets ranging from $24.00 to $32.00.

Analyst sentiment has remained unchanged over the past month, with the rating distribution holding steady at 4 Strong Buys and 1 Hold. This stability suggests the analyst community is maintaining conviction in the long-term thesis despite near-term execution challenges and the stock's steep decline. The wide gap between current trading levels and price targets indicates analysts view the recent selloff as overdone relative to Neffy's commercial potential and the company's market opportunity in needle-free epinephrine delivery.

The consensus reflects confidence that ARS Pharmaceuticals can eventually translate prescription growth into meaningful revenue scale and improved operating leverage, even as the path to profitability remains longer than initially anticipated. However, the single Hold rating serves as a reminder that not all analysts share equal enthusiasm, particularly given the consistent pattern of earnings misses and elevated cash burn rate.

Part 4: Technical Picture

The Barchart Technical Opinion shows a Sell signal at 88%, representing a slight improvement from last week's 100% Sell reading but a significant deterioration from last month's 56% Sell. This indicates mounting technical pressure as the stock approaches earnings, though the recent modest strengthening suggests some stabilization after the sharp year-to-date decline.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum remains negative but less extreme than longer timeframes
• Medium-term (100% Sell): Strong sell signal reflects clear weakness in the intermediate trend as the stock trades well below key moving averages
• Long-term (100% Sell): Maximum bearish reading confirms the sustained downtrend over the past year, with shares down 68% from 52-week highs

Trend Characteristics: The signal strength is rated as "Good" with a "Strengthening" direction, suggesting the technical setup is becoming more defined even as it remains bearish—a pattern that often precedes either a capitulation low or further breakdown.

The stock is trading at $6.05, positioned above its 5-day ($5.92), 10-day ($5.65), and 20-day ($5.95) moving averages, indicating some short-term stabilization. However, it remains well below all longer-term moving averages: the 50-day ($7.68), 100-day ($7.96), and 200-day ($8.81). This configuration—above short-term but below all long-term averages—suggests a potential dead-cat bounce within a broader downtrend rather than a genuine reversal.

The stock is testing resistance at its 20-day moving average of $5.95 while trading near its 52-week low of $6.66, creating a technically precarious setup heading into earnings. The elevated implied volatility of 116.19%—well above the historical volatility of 91.62%—confirms options traders are pricing in significant risk. With the stock below all major long-term moving averages and the technical opinion firmly in sell territory across medium and long-term timeframes, the setup is cautionary for earnings. A positive surprise could trigger a sharp short-covering rally given the oversold conditions, but any disappointment risks accelerating the downtrend toward new lows with limited technical support until the $5.00-$5.35 zone where recent trading activity has clustered.